Dr. Robert S. Call, M.D.
Allergy & Immunology (Allergy Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
VA license 0101048191
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Professional service for preparation and provision of 1 or more antigens | 1,740 | 102 |
| Test for allergy using allergenic extract | 1,576 | 32 |
| Test for allergy using allergenic extract injected into skin | 1,020 | 27 |
| Professional service for multiple injections of allergen | 675 | 41 |
| Professional service for single injection of allergen | 588 | 42 |
| Established patient office or other outpatient visit, 20-29 minutes | 143 | 124 |
| Test to measure expiratory airflow and volume | 47 | 43 |
| Established patient office or other outpatient visit, 10-19 minutes | 26 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 23 | 23 |
| New patient office or other outpatient visit, 30-44 minutes | 18 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Richmond, VA | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $1,235,049 in research payments for these studies, mostly to the institutions running them.
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
Sanofi US Services Inc. · Active, not recruiting · NCT06557772 - A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo
Incyte Corporation - A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine,…
Merck Sharp & Dohme LLC - A phase 2, parallel-group, double-blind, placebo-controlled study to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight with type 2…
Eli Lilly and Company - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - A phase 2 randomized doubleblind placebocontrolled parallelgroup doseranging study to investigate the efficacy and safety of PF07275315 in adult participants with inadequately controlled moderatetosevere asthma
Pfizer Inc. - Study of DONQ52 in Active Celiac Disease
Chugai Pharmaceutical Co., Ltd. - A phase 3 placebocontrolled doubleblinded randomized study to evaluate the efficacy safety and tolerability of a clostridioides difficile vaccine in adults 65 years of age and older
Pfizer Inc. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04530123
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.